EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/24/2025
Back to search
Official data from USPTO
G1 THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
G1 THERAPEUTICS
ST13
US500000090483777Class
5, 42
Filing
90483777
Registration
6847725
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
06/29/2025
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
01/22/2021
Registration date
09/13/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/13/2022
Last transaction
06/29/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2021-03-00
First use in commerce
2021-03-00
Drawing code
4
Owner type
65
Owner location
HOLB?K, DK
Examiner
RICHARDS, LESLIE
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
PHARMACOSMOS HOLDING A/S
G1 Therapeutics, Inc.
Representatives
Shannon Marie McKeon Dykema Gossett PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for myeloprotection and anti-tumor effects; pharmaceutical preparations for reducing side effects of chemotherapy; pharmaceutical preparations for use in oncologyimproving outcomes from chemotherapytreatment of cancer; therapeutic preparations for use in patients with cancer
Class 42
Pharmaceutical research and development; providing medical and scientific research information in the fields of oncologypharmaceuticalstherapiesdiseasesdisorders
Publications
History of USPTO decisions and trademark events.
30 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/24/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/24/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/24/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/24/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/24/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/12/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/13/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/13/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/06/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/05/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/27/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/26/2022
IUAF
USE AMENDMENT FILED
07/08/2022
EISU
TEAS STATEMENT OF USE RECEIVED
07/08/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/03/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/08/2022
PUBO
PUBLISHED FOR OPPOSITION
03/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/16/2022
ALIE
ASSIGNED TO LIE
01/27/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/26/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/20/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/19/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/19/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/28/2021
GNRT
NON-FINAL ACTION E-MAILED
07/28/2021
CNRT
NON-FINAL ACTION WRITTEN
07/28/2021
DOCK
ASSIGNED TO EXAMINER
07/17/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/24/2021
NWAP
NEW APPLICATION ENTERED
01/26/2021
Continuous trademark protection
Get notified about every new filing that threatens G1 THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.